Literature DB >> 16161006

Diagnostic and pathogenetic implications of the expression of hepatic transporters in focal lesions occurring in normal liver.

Sara Vander Borght1, Louis Libbrecht, Hans Blokzijl, Klaas Nico Faber, Han Moshage, Raymond Aerts, Werner Van Steenbergen, Peter L Jansen, Valeer J Desmet, Tania A Roskams.   

Abstract

Hepatocellular adenoma and focal nodular hyperplasia (FNH) are benign liver tumours. The differential diagnosis of these lesions and of well- to moderately differentiated hepatocellular carcinomas is often difficult but is very important in view of their different treatment. Although neither type of lesion is connected to the biliary tree, FNHs are cholestatic, whereas this is rarely the case for hepatocellular adenomas. This suggests that hepatocellular uptake and secretion of bile constituents is different in FNHs compared to adenomas. We therefore evaluated the expression and localization of hepatic transporters in hepatocellular adenomas, different types of FNH and well- to moderately differentiated hepatocellular carcinomas in non-cirrhotic liver and compared them with normal liver, using real-time RT-PCR and (semi-)quantitative immunohistochemistry. The parenchymal expression of the uptake transporter OATP2/8 (OATP1B1/3) was minimal or absent in adenoma, while there was strong and diffuse expression in FNH. We observed diffuse parenchymal expression of the basolateral export pump MRP3 in adenomas, while only reactive bile ductules and adjacent cholestatic hepatocytes were MRP3-positive in FNH. The MRP3/OATP2/8 expression pattern of atypical FNHs resembled that of adenomas, suggesting that both types of lesion are related. Most hepatocellular carcinomas showed decreased expression of one or more of the canalicular transporters (MDR1, MDR3, BSEP). The differences in transporter expression profile between FNHs and adenomas are most likely pathogenetically important and may explain why only FNHs are cholestatic. The finding that each type of focal lesion in non-cirrhotic liver has a specific transporter expression pattern may be useful in the establishment of a correct diagnosis by imaging or on needle biopsy. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16161006     DOI: 10.1002/path.1852

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  Ring-like enhancement of focal nodular hyperplasia with hepatobiliary-phase Gd-EOB-DTPA-enhanced magnetic resonance imaging: radiological-pathological correlation.

Authors:  Hiroyasu Fujiwara; Shigeki Sekine; Hiroaki Onaya; Kazuaki Shimada; Rintaro Mikata; Yasuaki Arai
Journal:  Jpn J Radiol       Date:  2011-10-19       Impact factor: 2.374

2.  Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience.

Authors:  Christian Grieser; Ingo G Steffen; Incken-Birthe Kramme; Hendrik Bläker; Ergin Kilic; Carmen Maria Perez Fernandez; Daniel Seehofer; Eckart Schott; Bernd Hamm; Timm Denecke
Journal:  Eur Radiol       Date:  2014-06       Impact factor: 5.315

Review 3.  Trafficking and other regulatory mechanisms for organic anion transporting polypeptides and organic anion transporters that modulate cellular drug and xenobiotic influx and that are dysregulated in disease.

Authors:  Michael Murray; Fanfan Zhou
Journal:  Br J Pharmacol       Date:  2017-04-24       Impact factor: 8.739

4.  Immunohistochemical Assessment of the Expression of Biliary Transportation Proteins MRP2 and MRP3 in Hepatocellular Carcinoma and in Cholangiocarcinoma.

Authors:  Cinthya Santos Cirqueira; Aloisio Sousa Felipe-Silva; Alda Wakamatsu; Lidiane Vieira Marins; Eziel Cavalcanti Rocha; Evandro Sobroza de Mello; Venâncio Avancini Ferreira Alves
Journal:  Pathol Oncol Res       Date:  2018-02-20       Impact factor: 3.201

5.  Hepatocyte transporter expression in FNH and FNH-like nodule: correlation with signal intensity on gadoxetic acid enhanced magnetic resonance images.

Authors:  Norihide Yoneda; Osamu Matsui; Azusa Kitao; Ryuuichi Kita; Kazuto Kozaka; Wataru Koda; Satoshi Kobayashi; Toshifumi Gabata; Hiroko Ikeda; Yasunori Sato; Yasuni Nakanuma
Journal:  Jpn J Radiol       Date:  2012-05-24       Impact factor: 2.374

6.  Liver Perfusion Modifies Gd-DTPA and Gd-BOPTA Hepatocyte Concentrations Through Transfer Clearances Across Sinusoidal Membranes.

Authors:  Jean-Luc Daire; Benjamin Leporq; Valérie Vilgrain; Bernard E Van Beers; Sabine Schmidt; Catherine M Pastor
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-08       Impact factor: 2.441

Review 7.  The expression and function of organic anion transporting polypeptides in normal tissues and in cancer.

Authors:  Amanda Obaidat; Megan Roth; Bruno Hagenbuch
Journal:  Annu Rev Pharmacol Toxicol       Date:  2011-08-15       Impact factor: 13.820

8.  Vinculin and cellular retinol-binding protein-1 are markers for quiescent and activated hepatic stellate cells in formalin-fixed paraffin embedded human liver.

Authors:  Elke Van Rossen; Sara Vander Borght; Leo Adrianus van Grunsven; Hendrik Reynaert; Veerle Bruggeman; Rune Blomhoff; Tania Roskams; Albert Geerts
Journal:  Histochem Cell Biol       Date:  2008-12-04       Impact factor: 4.304

9.  Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: a possible subtype with mature hepatocyte nature.

Authors:  Norihide Yoneda; Osamu Matsui; Azusa Kitao; Ryuichi Kita; Kazuto Kozaka; Wataru Koda; Satoshi Kobayashi; Toshifumi Gabata; Hiroko Ikeda; Yasuni Nakanuma
Journal:  Jpn J Radiol       Date:  2013-06-16       Impact factor: 2.374

10.  Beta-catenin-activated hepatocellular adenoma showing hyperintensity on hepatobiliary-phase gadoxetic-enhanced magnetic resonance imaging and overexpression of OATP8.

Authors:  Norihide Yoneda; Osamu Matsui; Azusa Kitao; Kazuto Kozaka; Toshifumi Gabata; Motoko Sasaki; Yasuni Nakanuma; Kiyoshi Murata; Toru Tani
Journal:  Jpn J Radiol       Date:  2012-08-23       Impact factor: 2.374

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.